Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.23 -4.7%	$1.33	$0.86 ▼ $3.78	$269.04M	0.31	3.27 million shs	3.63 million shs
CGEM Cullinan Therapeutics	$7.67 -6.0%	$8.16	$6.85 ▼ $21.01	$452.64M	-0.04	535,128 shs	663,002 shs
ICVX Icosavax	$15.31	$15.32	$4.75 ▼ $16.10	$766.88M	1.28	1.22 million shs	N/A
TRML Tourmaline Bio	$16.64 -1.1%	$16.73	$11.56 ▼ $29.79	$427.41M	2.05	274,186 shs	294,434 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-8.21%	+12.84%	-24.07%	-44.84%
CGEM Cullinan Therapeutics	0.00%	-10.92%	-2.79%	-9.98%	-54.37%
ICVX Icosavax	0.00%	0.00%	0.00%	0.00%	0.00%
TRML Tourmaline Bio	0.00%	-15.45%	+8.97%	-2.97%	+7.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.2341 of 5 stars	4.5	3.0	0.0	0.0	0.0	3.3	0.6
CGEM Cullinan Therapeutics	1.7195 of 5 stars	3.5	0.0	0.0	0.0	2.2	1.7	0.6
ICVX Icosavax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	1.9951 of 5 stars	3.5	3.0	0.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	586.54% Upside
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	291.13% Upside
ICVX Icosavax	0.00	N/A	N/A	N/A
TRML Tourmaline Bio	3.00	Buy	$49.33	196.47% Upside

Current Analyst Ratings Breakdown

Latest ICVX, ALLO, CGEM, and TRML Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,451.90	N/A	N/A	$2.01 per share	0.61
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.14 per share	N/A
ICVX Icosavax	$580K	1,322.20	N/A	N/A	$5.47 per share	2.80
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
CGEM Cullinan Therapeutics	-$167.38M	-$2.91	N/A	N/A	N/A	N/A	-29.47%	-28.19%	8/14/2025 (Estimated)
ICVX Icosavax	-$91.76M	-$2.22	N/A	N/A	N/A	N/A	-43.06%	-39.53%	N/A
TRML Tourmaline Bio	-$73.21M	-$3.21	N/A	N/A	N/A	N/A	-26.75%	-26.11%	8/6/2025 (Estimated)

Latest ICVX, ALLO, CGEM, and TRML Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
ICVX Icosavax	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
CGEM Cullinan Therapeutics	N/A	11.62	11.62
ICVX Icosavax	N/A	18.06	18.06
TRML Tourmaline Bio	N/A	33.87	33.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CGEM Cullinan Therapeutics	86.31%
ICVX Icosavax	92.59%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CGEM Cullinan Therapeutics	6.07%
ICVX Icosavax	30.59%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
CGEM Cullinan Therapeutics	30	59.01 million	55.43 million	Optionable
ICVX Icosavax	60	50.09 million	34.77 million	Optionable
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable

ICVX, ALLO, CGEM, and TRML Headlines

Recent News About These Companies

Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

June 10, 2025 | marketbeat.com

Tourmaline Bio Elects Directors and Ratifies Auditor

June 6, 2025 | tipranks.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE

June 6, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Trading Up 7.2% - Here's What Happened

June 5, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from Brokerages

May 31, 2025 | marketbeat.com

H.C. Wainwright maintains $50 target on Tourmaline Bio stock

May 29, 2025 | uk.investing.com

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

May 29, 2025 | msn.com

Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 28, 2025 | marketbeat.com

Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings

May 27, 2025 | marketbeat.com

29,844 Shares in Tourmaline Bio, Inc. (NASDAQ:TRML) Purchased by Rafferty Asset Management LLC

May 25, 2025 | marketbeat.com

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

May 23, 2025 | msn.com

Wexford Capital LP Purchases New Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 22, 2025 | marketbeat.com

Tourmaline shares waver as investors mull mid-stage pacibekitug data

May 21, 2025 | thepharmaletter.com

Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win

May 21, 2025 | fiercebiotech.com

Tourmaline Bio posts mid-stage data for anti-inflammatory agent

May 21, 2025 | msn.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20, 2025 | seekingalpha.com

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 19, 2025 | globenewswire.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Why Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%

May 3, 2025 | aaii.com

Tourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 3, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

ICVX, ALLO, CGEM, and TRML Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.23 -0.06 (-4.65%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.26 +0.03 (+2.11%)

As of 06/20/2025 07:57 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Cullinan Therapeutics NASDAQ:CGEM

$7.67 -0.49 (-6.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.66 0.00 (-0.07%)

As of 06/20/2025 05:38 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Icosavax NASDAQ:ICVX

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Tourmaline Bio NASDAQ:TRML

$16.64 -0.19 (-1.13%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$16.64 0.00 (0.00%)

As of 06/20/2025 06:54 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time